Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Status:
Completed
Trial end date:
2017-04-05
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial was is to assess the effect of treatment with deferasirox
combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with low-
and int-1-risk myelodysplastic syndrome. The addition of deferasirox to erythropoietin can
lead to a potential synergism with the reduction of reactive oxygen species, through both the
NF-kB pathway and the control of free toxic iron. This may create a better environment in the
bone marrow for a better response with erythropoietin.
This study was designed to test in a prospective way the combination of deferasirox with
erythropoietin in terms of their effect on hematopoiesis.